Aurelinate long-term safety extension analysis plan

EVP-0010HEOR studyAurelinIdeaRisk lowSponsor: Company

TFDr. Tomás FerreiraGlobal Medical Lead, Aurelin

Evidence gap: Long-term safety versus existing JAK inhibitors
Objective: SO-ARL-01
Research question: How does the aurelinate long-term safety profile compare with approved JAK inhibitors?
Design: Indirect treatment comparison / NMA
Investigator: —
Institution: —
Countries: United States
Data source: Published trials
Submitted: 09 Sept 2026
Approved: —
Contract / ethics: Not startedEthics not required
Budget / spend: $0 of $180k
0%
Enrolment: n/a

Workflow

Evidence-generation workflow (PRD §17); Rejected is a terminal branch from any review stage.

Current stageIdeaDemo action — not persisted

Review stages passed, derived from workflow position

Study milestones from CTMS (INT-06)

No milestones yet

No linked publications

Insights citing the evidence gap "Long-term safety versus existing JAK inhibitors"

No linked insights

No related risks

No dependencies recorded

No audit events for this record

Create, update, approve and export events appear here with user, timestamp, previous and new values.